Company intelligence / Profile preview

Immunis, Inc.

Irvine, California, United Statesimmunisbiomedical.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 1/2a clinical trial demonstrating safety, tolerability and suggestive efficacy of IMM01-STEM in people with age-related muscle atrophy. Patients experienced improvements in quality-of-life measures related to physical function and pain as well as a clinically relevant increase in gait speed. FDA granted permission to proceed with Phase 2 clinical trials.

Therapeutic areas: Metabolic DisordersRheumatologyEndocrinologyImmunologyOther
Modalities: Cellular secretome therapiesMulti-active biologicsStem cell-derived secretomes
Industry: Biotech

Drug pipeline

2 assets

IMM01-STEM

1 more asset in the full pipeline.

Request access →

Partnerships

Springbok Analytics (for MRI-based AI Muscle Analysis Technology)

Beyond the preview

Go deeper on Immunis, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunis, Inc..

Explore the full profile